Impact of Inflammatory Indexes and Gene Scores in Prediction of Atrial Fibrillation
Trial Snapshot
- Phase
- Not Applicable
- Status
- Recruiting
- Sponsor
- Enrollment
- 205
- Locations
- 2
- Primary Endpoint
- Recurrence of AF
Study Overview
Brief Summary
Because of the high recurrence rates following electrical cardioversion and high morbidity in AF patients there is a need to explore prediction models for AF recurrence following ECV. Previous studies have primarily focused on high-sensitivity CRP (hsCRP), CRP, and IL-6, while other inflammatory indexes and gene scores might hold greater value.
This prospective cohort study is planning to include 205 patients with persistent atrial fibrillation, planned for electrical cardioversion, and >18 years at two medium-sized hospitals in Sweden. Blood samples will be collected prior to electrical cardioversion and at 7-, 30-, 90-, and 180-days follow-up. Atrial fibrillation recurrence will be evaluated at follow-up or upon patient request and diagnosed with 12-lead ECG.
Study Design
- Study Type
- Observational
- Observational Model
- Cohort
- Time Perspective
- Prospective
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- •persistent atrial fibrillation (ICD-10 I48.1), age over 18 years
Exclusion Criteria
- •autoimmune diseases, inflammatory diseases, acute or chronic liver dysfunction, ongoing infectious diseases, thyroid disorders, or any other conditions known to impact inflammatory activity (including medication use and hematological diseases)
Outcomes
Primary Outcomes
Recurrence of AF
Time Frame: During follow-up (post ECV, day 7, 30, 90, and 180)
Recurrence of atrial fibrillation or atrial flutter recorded on 12-lead ECG or through pacemaker interpretation
Secondary Outcomes
- Fluctuations of biomarkers and gene expression during follow-up(During follow-up (post ECV, day 7, 30, 90, and 180))
Investigators
Jakob Hytting
MD
Vrinnevi Hospital